10:09
AstraZeneca and Stone Pharmaceutical Group reach nearly $2 billion cardiovascular drug authorization protocol
On October 7th, Jin10 News reported that AstraZeneca and Chi-Med (01093.HK) have reached an exclusive licensing protocol to advance the development of a preclinical innovative small molecule lipoprotein(a) (Lp(a)) inhibitor to enhance the cardiovascular product pipeline. AstraZeneca said it will pay Chi-Med up to $1.92 billion in milestone and royalty payments and $100 million in upfront payment.